Figure 4. Evaluation of68Ga-HZ20 in the rhACE2-intraperitoneal liver model.
(A) PET imaging with in situ injection of different doses of
rhACE2 in the liver. The white circle indicates the liver injection site
(L, H, B stands for liver, heart and bladder). (B) Comparison of SUVmax
in the liver in Figure 4A and Figure S7. (C) The ratio of liver to
muscle SUVmax. (D) Comparison of liver tissue % ID/g. (E) Correlation
analysis between SUVmax and rhACE2 doses at 60 min after injection. (F)
Western blot of rhACE2 at the injection site.